Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DISULFIRAM vs CO-GESIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Disulfiram irreversibly inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion, leading to aversive effects such as flushing, nausea, and hypotension.
CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.
Alcohol dependence (FDA-approved),Off-label: Cocaine dependence (limited evidence)
FDA: Management of moderate to moderately severe pain where an opioid is appropriate.,Off-label: Not commonly used off-label; may be considered for refractory pain conditions.
250 mg orally once daily, increased to 500 mg orally once daily if needed; maintenance dose typically 250 mg per day (range 125-500 mg).
1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
Approximately 7–10 hours for parent drug; however, the disulfiram-ethanol reaction can persist up to 14 days due to irreversible inhibition of aldehyde dehydrogenase (ALDH) and slow regeneration of the enzyme. The active metabolite, diethyldithiocarbamate, has a half-life of about 15 hours.
Terminal elimination half-life is approximately 2–4 hours in adults with normal renal function; prolonged in renal impairment.
Disulfiram is rapidly metabolized in the liver to diethyldithiocarbamate, which is further metabolized; it is primarily excreted in urine and feces.
Hydrocodone: primarily hepatic via CYP3A4-mediated N-demethylation to norhydrocodone (active) and O-demethylation via CYP2D6 to hydromorphone (active). Acetaminophen: hepatic via glucuronidation and sulfation; minor oxidation by CYP2E1 to NAPQI (toxic metabolite).
Primarily renal as metabolites; approximately 80% of a dose is excreted in urine as glucuronide conjugates and other metabolites, with less than 20% excreted in feces via bile. A small amount is eliminated unchanged in urine.
Primarily renal (60–70% as unchanged drug and metabolites); minor biliary/fecal excretion (<5%).
Approximately 96% bound primarily to albumin and also to lipoproteins.
<20%; primarily binds to albumin.
Approximately 2–4 L/kg, indicating extensive tissue distribution and accumulation, particularly in adipose tissue due to lipophilicity.
1.2–1.9 L/kg; suggests extensive distribution into total body water.
Rapidly and almost completely absorbed after oral administration; absolute bioavailability is approximately 70–90% due to first-pass metabolism in the liver. No parenteral forms are approved; only oral route (tablets) is used clinically.
Oral: 85–95%; rectal: 70–80%.
No dose adjustment required for renal impairment; no specific GFR-based guidelines exist; use with caution in severe renal impairment.
GFR 30-59 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8 hours; GFR <10 m L/min: Administer every 12 hours; avoid use in severe renal impairment.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment, but monitor liver function. Not recommended in active liver disease.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% and extend interval to every 8 hours; Child-Pugh Class C: Use not recommended due to hepatotoxicity risk.
Not recommended for use in patients under 18 years due to lack of established safety and efficacy.
Children ≥2 years: Hydrocodone 0.1-0.2 mg/kg/dose (max 5 mg/dose) plus acetaminophen 10-15 mg/kg/dose (max 500 mg/dose) orally every 4-6 hours as needed; maximum 5 doses per day.
Initiate at lower dose (125 mg/day) due to age-related decreased function; monitor closely for adverse effects.
Start at lower end of dosing range (e.g., 1 tablet every 6 hours) due to increased sensitivity to opioids and renal clearance decline; monitor for respiratory depression and sedation.
Disulfiram should never be administered to a patient who is in a state of alcohol intoxication or without the patient's full knowledge and consent. The patient must be fully informed of the disulfiram-alcohol reaction.
Risk of addiction, abuse, and misuse; serious, life-threatening or fatal respiratory depression from opioid use; accidental ingestion of acetaminophen can cause acute liver failure; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants.
Hepatotoxicity including hepatitis and hepatic failure; peripheral neuropathy; optic neuritis; psychotic reactions; hypersensitivity; risk of severe disulfiram-alcohol reaction if alcohol is consumed.
Addiction, abuse, and misuse; respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risk with concomitant use of CNS depressants; severe hypotension; seizures; serotonin syndrome; adrenal insufficiency; hepatotoxicity (acetaminophen overdose); hypersensitivity reactions; constipation; urinary retention; impaired mental/physical abilities.
Concurrent use of alcohol or alcohol-containing preparations; metronidazole; paraldehyde; severe myocardial disease; coronary occlusion; psychosis; severe hepatic impairment; hypersensitivity to disulfiram or other thiuram derivatives.
Hypersensitivity to hydrocodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; known or suspected GI obstruction (e.g., paralytic ileus); use of MAO inhibitors (concurrent or within 14 days).
Avoid foods and products containing alcohol: sauces (e.g., wine sauces, beer batter), vinegar (especially red/white wine vinegar), marinades, ripe fruits (fermentation can produce trace alcohol), some desserts (e.g., tiramisu, fruitcakes), alcohol-infused chocolates, non-alcoholic beer/wine (may contain up to 0.5% alcohol). Also avoid mouthwashes, breath sprays, and hand sanitizers with ethanol. Some medications like paraldehyde, chloral hydrate, and metronidazole may cross-react. Even alcohol in cooking may not fully evaporate and can trigger a reaction.
Avoid grapefruit and grapefruit juice as they may alter metabolism of hydrocodone. Take with food if gastrointestinal upset occurs. Avoid alcohol-containing foods or beverages. No other significant food interactions.
Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxic effects at high doses. Avoid unless benefit outweighs risk. Second and third trimesters: No specific malformation patterns reported; however, theoretical risk of disulfiram-ethanol reaction causing fetal hypoxia due to maternal acetaldehyde accumulation. Use only if essential and with strict alcohol avoidance.
First trimester: No adequate studies; risk cannot be ruled out. Second and third trimesters: Avoid prolonged use or high doses near term due to potential premature closure of ductus arteriosus and oligohydramnios.
Excreted into breast milk in small amounts (M/P ratio not established). No adverse effects reported in nursing infants. However, theoretical risk of disulfiram-ethanol reaction if mother consumes alcohol. Recommend caution and discuss with healthcare provider; generally consider compatible with breastfeeding if mother abstains from alcohol.
No data on M/P ratio; use with caution. Low molecular weight may be excreted into breast milk; monitor infant for sedation or respiratory depression.
No specific dose adjustment recommended in pregnancy. Pharmacokinetic studies in pregnancy not available. Use lowest effective dose (typically 250 mg/day) to minimize risks. Avoid higher loading doses. Discontinue if signs of hepatotoxicity occur.
No specific dose adjustments required; however, due to increased renal clearance in pregnancy, shortened dosing intervals or higher doses may be needed for adequate analgesia. Monitor clinical response and adjust accordingly.
Disulfiram irreversibly inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion, leading to severe nausea, vomiting, hypotension, and flushing. Avoid use in patients with severe heart disease, psychosis, or cirrhosis. Monitor LFTs and CBC at baseline and periodically. Disulfiram may also inhibit CYP450 enzymes (CYP2E1, CYP1A2, CYP3A4), potentiating warfarin, phenytoin, and theophylline. Onset of aversion therapy requires 12-48 hours after the last alcohol dose; maintain alcohol-free period of 24 hours before starting. Duration of action persists up to 14 days after discontinuation. Inadvertent alcohol exposure in topical products (mouthwash, colognes) can trigger reactions.
Co-Gesic is a fixed-dose combination of hydrocodone and acetaminophen. Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen dose should not exceed 4 g. Hydrocodone is a Schedule II controlled substance with abuse potential. Use with caution in patients with respiratory compromise, COPD, or sleep apnea. Avoid concurrent use with other CNS depressants including alcohol. In opioid-tolerant patients, withdrawal may occur if discontinued abruptly.
Avoid all forms of alcohol, including beverages, mouthwash, cough syrup, cooking wine, vinegar, aftershave, and hand sanitizers.,Reaction to alcohol includes severe flushing, nausea, vomiting, chest pain, difficulty breathing, and blurred vision; seek emergency care if symptoms occur.,The disulfiram-alcohol reaction can be fatal even with small amounts of alcohol.,Inform all healthcare providers (including dentists) that you are taking disulfiram.,Reactions may occur up to 14 days after stopping the medication.,Do not take disulfiram if you have recently consumed alcohol; wait at least 12 hours after the last drink.,Carry a medical alert card or wear a bracelet stating you are on disulfiram.,Report any signs of liver toxicity: yellowing of eyes/skin, dark urine, severe fatigue.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol while taking this medication due to risk of liver damage and increased sedation.,Do not take other medications containing acetaminophen (Tylenol, many cold/flu products) to avoid exceeding the maximum daily dose (4 grams).,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of children and dispose of unused medication properly (take-back programs preferred).,Do not crush or chew extended-release formulations (if applicable).,Report signs of liver injury (yellowing skin/eyes, dark urine, abdominal pain) or respiratory depression (slow/shallow breathing) immediately.
"Rifapentine, a potent inducer of cytochrome P450 enzymes, significantly increases the metabolism of disulfiram by inducing hepatic CYP3A4 and other metabolic pathways. This induction reduces disulfiram plasma concentrations, potentially diminishing its therapeutic efficacy in maintaining alcohol aversion. The interaction may lead to an increased risk of alcohol consumption relapse and associated clinical consequences."
"Disulfiram inhibits aldehyde dehydrogenase, leading to acetaldehyde accumulation, but also inhibits CYP3A4 and other CYP enzymes. Palbociclib is primarily metabolized by CYP3A4 and is a substrate of this enzyme. Coadministration with disulfiram can significantly increase palbociclib serum concentrations, raising the risk of dose-dependent toxicities such as neutropenia, infections, and fatigue."
"Disulfiram irreversibly inhibits aldehyde dehydrogenase and also suppresses the activity of cytochrome P450 (CYP) 2D6 and other CYP enzymes, thereby reducing the hepatic metabolism of venlafaxine. This can lead to increased plasma concentrations of venlafaxine and its active metabolite O-desmethylvenlafaxine, elevating the risk of dose-dependent adverse effects such as hypertension, nausea, dizziness, and serotonin syndrome. Additionally, disulfiram's own metabolism may be affected, potentially increasing the severity of disulfiram-ethanol reactions."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DISULFIRAM vs CO-GESIC, answered by our medical review team.
DISULFIRAM is a Aldehyde Dehydrogenase Inhibitor that works by Disulfiram irreversibly inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion, leading to aversive effects such as flushing, nausea, and hypotension.. CO-GESIC is a Opioid Analgesic Combination that works by CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DISULFIRAM and CO-GESIC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DISULFIRAM is: 250 mg orally once daily, increased to 500 mg orally once daily if needed; maintenance dose typically 250 mg per day (range 125-500 mg).. The standard adult dose of CO-GESIC is: 1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DISULFIRAM and CO-GESIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DISULFIRAM is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxic effects at high doses. Avoid unless benefit outweighs risk. Second and third trimesters: . CO-GESIC is classified as Category C. First trimester: No adequate studies; risk cannot be ruled out. Second and third trimesters: Avoid prolonged use or high doses near term due to potential premature closure of ductu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.